NCT02894515

Bioequivalence Study of Idalopirdine in Healthy Subjects

Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 10 mg Commercial Tablet (Test) to the 10 mg Clinical Tablet (Reference)

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate whether 2 different tablet compositions are similar regarding absorption (uptake) in the body. One composition was used in the clinical development program and the other is intended for the market

Conditions

• Bioequivalence

Interventions

Type	Name	Description
DRUG	Idalopirdine commercial tablet (test)	single dose, 10 mg, oral
DRUG	Idalopirdine clinical tablet (reference)	single dose, 10 mg, oral

Timeline

• Start date: 2016-09-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2016-09-09
• Last updated: 2016-11-11

Locations

1 site across 1 country: United Kingdom